Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer

BACKGROUND Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their si...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate Vol. 69; no. 13; pp. 1387 - 1397
Main Authors: Gatti, Gerardo, Quintar, Amado A., Andreani, Virginia, Nicola, Juan P., Maldonado, Cristina A., Masini-Repiso, Ana Maria, Rivero, Virginia E., Maccioni, Mariana
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15-09-2009
Wiley-Liss
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract BACKGROUND Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma. METHODS To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU‐145. RESULTS TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU‐145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF‐κB and increasing the expression of pro‐inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant‐negative mutants diminished LPS‐induced activation of NF‐κB, showing that DU‐145 cells activate the NF‐κB through MyD88‐dependent signaling pathways. CONCLUSIONS We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387–1397, 2009. © 2009 Wiley‐Liss, Inc.
AbstractList BACKGROUND Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma. METHODS To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU‐145. RESULTS TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU‐145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF‐κB and increasing the expression of pro‐inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant‐negative mutants diminished LPS‐induced activation of NF‐κB, showing that DU‐145 cells activate the NF‐κB through MyD88‐dependent signaling pathways. CONCLUSIONS We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387–1397, 2009. © 2009 Wiley‐Liss, Inc.
Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll-like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma. To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU-145. TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU-145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF-kappaB and increasing the expression of pro-inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant-negative mutants diminished LPS-induced activation of NF-kappaB, showing that DU-145 cells activate the NF-kappaB through MyD88-dependent signaling pathways. We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387-1397, 2009. (c) 2009 Wiley-Liss, Inc.
Author Masini-Repiso, Ana Maria
Rivero, Virginia E.
Gatti, Gerardo
Maldonado, Cristina A.
Maccioni, Mariana
Quintar, Amado A.
Andreani, Virginia
Nicola, Juan P.
Author_xml – sequence: 1
  givenname: Gerardo
  surname: Gatti
  fullname: Gatti, Gerardo
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
– sequence: 2
  givenname: Amado A.
  surname: Quintar
  fullname: Quintar, Amado A.
  organization: Centro de Microscopía Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
– sequence: 3
  givenname: Virginia
  surname: Andreani
  fullname: Andreani, Virginia
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
– sequence: 4
  givenname: Juan P.
  surname: Nicola
  fullname: Nicola, Juan P.
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
– sequence: 5
  givenname: Cristina A.
  surname: Maldonado
  fullname: Maldonado, Cristina A.
  organization: Centro de Microscopía Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
– sequence: 6
  givenname: Ana Maria
  surname: Masini-Repiso
  fullname: Masini-Repiso, Ana Maria
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
– sequence: 7
  givenname: Virginia E.
  surname: Rivero
  fullname: Rivero, Virginia E.
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
– sequence: 8
  givenname: Mariana
  surname: Maccioni
  fullname: Maccioni, Mariana
  email: mmaccioni@bioclin.fcq.unc.edu.ar
  organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21831154$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19496069$$D View this record in MEDLINE/PubMed
BookMark eNp9kE9T2zAQxTUdmCahvfABGF24dMZUsmTLOjKQhnZC6UBajhpFWoHA2EYSf_Lta5M03HrY2cvvvbf7JminaRtAaJ-SI0pI_rULbTzKiaz4BzSmRIqMEF7soDHJBck4ZWKEJjHeEdLjJP-IRlRyWZJSjtHj9LULEKNvG9w6vGjrOqv9PeAABrrUBsyxb3C6BTzEJJ0A39S6sXgYnyLWMbbG6zQ4vPh0-8ZGeIbg02rw3OqMbgyET2jX6TrC583eQ7-_TRcnZ9n8Yvb95HieGSYLntkScqm1qbSlS8uEdA44s2C0FaRgUhu6FKANOFNKcFxUhbWGs5KKpbOVYXvoy9rX9PkxgFNd8A86rBQlauhNDYept956-GANd0_LB7Dv6KaoHjjcADoaXbvQ_-LjlstpxSgtBiO65l58Dav_RKpflxdX_8KztcbHBK9bjQ73qhRMFOr650xdnc9P6eWPP-qM_QW00Joa
CODEN PRSTDS
CitedBy_id crossref_primary_10_1016_j_tips_2016_06_010
crossref_primary_10_1007_s10620_021_06973_9
crossref_primary_10_1136_jclinpath_2011_200402
crossref_primary_10_1002_pros_21150
crossref_primary_10_1158_0008_5472_CAN_10_2210
crossref_primary_10_3347_PHD_22160
crossref_primary_10_3892_ijo_2014_2479
crossref_primary_10_1016_j_micres_2023_127596
crossref_primary_10_17650_2070_9781_2022_23_3_41_47
crossref_primary_10_3390_cancers6021065
crossref_primary_10_1016_j_bbcan_2012_10_006
crossref_primary_10_3390_ijms16034471
crossref_primary_10_1016_j_anireprosci_2011_03_008
crossref_primary_10_4161_onci_22089
crossref_primary_10_1017_S0007114511007227
crossref_primary_10_1371_journal_pone_0197327
crossref_primary_10_1371_journal_pone_0016205
crossref_primary_10_1007_s00251_012_0674_5
crossref_primary_10_5213_inj_2014_18_1_10
crossref_primary_10_1002_pros_21423
crossref_primary_10_1016_j_canlet_2012_01_040
crossref_primary_10_3109_10520295_2013_785592
crossref_primary_10_3892_or_2023_8560
crossref_primary_10_1016_j_canlet_2015_08_004
crossref_primary_10_1371_journal_pone_0179897
crossref_primary_10_1186_s13058_021_01418_7
crossref_primary_10_3390_ph3103127
crossref_primary_10_1002_pros_21115
crossref_primary_10_1007_s00018_011_0864_6
crossref_primary_10_1002_pros_23655
crossref_primary_10_1016_j_prp_2024_155379
crossref_primary_10_1002_pbc_24211
crossref_primary_10_1530_REP_11_0163
crossref_primary_10_3389_fimmu_2014_00352
crossref_primary_10_3389_fimmu_2022_941667
crossref_primary_10_1016_j_urology_2017_09_026
crossref_primary_10_1016_j_jri_2013_05_002
crossref_primary_10_1111_j_1365_2605_2012_01288_x
crossref_primary_10_1007_s11912_024_01520_x
crossref_primary_10_1007_s11154_023_09838_w
crossref_primary_10_1099_jmm_0_024877_0
crossref_primary_10_1038_nrurol_2017_167
crossref_primary_10_1007_s40291_018_0361_9
crossref_primary_10_1016_j_bbadis_2012_09_002
crossref_primary_10_1002_cbin_10755
crossref_primary_10_1007_s00345_011_0690_3
crossref_primary_10_1016_j_oooo_2020_01_001
crossref_primary_10_1016_j_mcp_2014_01_006
crossref_primary_10_4103_jcrt_jcrt_2032_21
crossref_primary_10_1155_2011_609579
crossref_primary_10_4142_jvs_2015_16_3_281
crossref_primary_10_1152_physrev_00021_2019
Cites_doi 10.1097/01.ju.0000108131.43160.77
10.4049/jimmunol.172.2.1256
10.4049/jimmunol.178.5.3186
10.1128/IAI.00593-06
10.1093/jnci/85.3.200
10.1111/j.1525-1438.2007.01008.x
10.1189/jlb.1005597
10.1097/MOU.0b013e3282f9b3b7
10.1038/ni1112
10.1038/sj.onc.1210911
10.1073/pnas.92.10.4337
10.3322/canjclin.49.1.8
10.1074/jbc.M305536200
10.1111/j.1464-410X.2007.07091.x
10.1158/0008-5472.CAN-05-2078
10.1093/jnci/dji070
10.1227/01.NEU.0000249280.61761.2E
10.1095/biolreprod.106.053967
10.1023/A:1020110718701
10.1159/000151602
10.1002/mc.20325
10.1084/jem.20070325
10.1146/annurev.immunol.21.120601.141126
10.1002/pros.10317
10.4049/jimmunol.174.9.5781
10.1038/sj.onc.1210904
10.1097/00001648-200201000-00012
10.1016/j.urology.2004.12.028
10.4049/jimmunol.168.3.1435
10.1128/JCM.37.6.1863-1870.1999
10.1128/IAI.73.2.687-694.2005
10.1038/nri2079
10.1016/j.molimm.2007.01.022
10.1158/0008-5472.CAN-03-3280
10.1158/1055-9965.EPI-06-0429
10.1158/0008-5472.CAN-07-0079
10.1038/nrc2090
10.1002/pros.20562
10.1038/ni1569
ContentType Journal Article
Copyright Copyright © 2009 Wiley‐Liss, Inc.
2009 INIST-CNRS
Copyright_xml – notice: Copyright © 2009 Wiley‐Liss, Inc.
– notice: 2009 INIST-CNRS
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1002/pros.20984
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0045
EndPage 1397
ExternalDocumentID 10_1002_pros_20984
19496069
21831154
PROS20984
ark_67375_WNG_SMLD1RJV_H
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET)
  funderid: PEI 6557
– fundername: Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT)
  funderid: PICT 2002 11944; PICT 2006 02369
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
TEORI
UB1
V2E
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
XG1
XV2
ZZTAW
~IA
~WT
.GJ
3O-
AAVGM
ABEML
ABHUG
ABWRO
ACSCC
ACXME
ADAWD
ADDAD
AFFNX
AFVGU
AGJLS
EBD
EMOBN
IQODW
M6P
PALCI
RIWAO
RJQFR
SAMSI
SV3
ZA5
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c3954-d6e29aac8ad1bd379ffe43decad70539ac1b7eacefc69ef4785ddc43617bfd8c3
IEDL.DBID 33P
ISSN 0270-4137
IngestDate Thu Nov 21 22:50:36 EST 2024
Sat Sep 28 07:45:47 EDT 2024
Sun Oct 22 16:07:21 EDT 2023
Sat Aug 24 01:01:55 EDT 2024
Mon Nov 18 03:20:00 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords Histological grading
Andrology
Nephrology
Urinary system disease
Toll like receptor 4
tumor immunology
Prostate disease
Gynecology
Toll-like receptor 4
Gleason grade
Inflammation
Malignant tumor
Association
Immunology
Urogenital system
Male genital diseases
Prostate cancer
Prostate
Cancer
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3954-d6e29aac8ad1bd379ffe43decad70539ac1b7eacefc69ef4785ddc43617bfd8c3
Notes Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT) - No. PICT 2002 11944; No. PICT 2006 02369
istex:23B0D9F1BFB840A8770E8077A986F68E83F11E3F
ark:/67375/WNG-SMLD1RJV-H
Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET) - No. PEI 6557
ArticleID:PROS20984
PMID 19496069
PageCount 11
ParticipantIDs crossref_primary_10_1002_pros_20984
pubmed_primary_19496069
pascalfrancis_primary_21831154
wiley_primary_10_1002_pros_20984_PROS20984
istex_primary_ark_67375_WNG_SMLD1RJV_H
PublicationCentury 2000
PublicationDate 15 September 2009
PublicationDateYYYYMMDD 2009-09-15
PublicationDate_xml – month: 09
  year: 2009
  text: 15 September 2009
  day: 15
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle The Prostate
PublicationTitleAlternate Prostate
PublicationYear 2009
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Liss
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Liss
References Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004; 171: S36-S40.
Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005; 65: 11771-11778.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67: 774-781.
Quintar AA, Roth FD, De Paul AL, Aoki A, Maldonado CA. Toll-like receptor 4 in rat prostate: Modulation by testosterone and acute bacterial infection in epithelial and stromal cells. Biol Reprod 2006; 75: 664-672.
Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007; 100: 733-737.
Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 525-532.
Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 352-355.
Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-3197.
Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun 2009; 1: 59-68.
Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: A double-edged sword. Oncogene 2008; 27: 218-224.
Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64: 2918-2922.
O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364.
Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007; 67: 10519-10527.
Nickel JC, Moon T. Chronic bacterial prostatitis: An evolving clinical enigma. Urology 2005; 66: 2-8.
Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008; 9: 361-368.
Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002; 21: 3-16.
Tanner MA, Shoskes D, Shahed A, Pace NR. Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and "nonbacterial" prostatitis. J Clin Microbiol 1999; 37: 1863-1870.
Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, Morrison RP, Arditi M. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168: 1435-1440.
Muthukuru M, Jotwani R, Cutler CW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 2005; 73: 687-694.
He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-2859.
Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate. Cancer Res 1999; 59: 5002-5011.
Chen Q, Fischer A, Reagan JD, Yan L, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci 1995; 92: 4337-4341.
Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13: 72-79.
Lee JW, Choi JJ, Seo ES, Kim MJ, Kim WY, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007; 46: 941-947.
Gatti G, Rivero V, Motrich RD, Maccioni M. Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and pro-inflammatory mediators upon LPS stimulation. J Leukoc Biol 2006; 79: 989-998.
Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, Kyburz D. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256-1265.
Nolte MA, Leibundgut-Landmann S, Joffre O, Reis e Sousa C. Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo. J Exp Med 2007; 204: 1487-1495.
Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-346.
Smith MF Jr, Mitchell A, Li G, Ding S, Fitzmaurice AM, Ryan K, Crowe S, Goldberg JB. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003; 278: 32552-32560.
Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167.
Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008; 18: 315-319.
Chicoine MR, Zahner M, Won EK, Kalra RR, Kitamura T, Perry A, Higashikubo R. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 2007; 60: 372-380.
Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005; 174: 5781-5788.
Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
Mackern-Oberti JP, Maccioni M, Cuffini C, Gatti G, Rivero VE. Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll-like receptors 4 and 2 and MyD88 to the inclusion. Infect Immun 2006; 74: 6973-6981.
König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004; 58: 121-129.
Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 2008; 18: 300-305.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2004; 64
2006; 74
1995; 92
2006; 75
2007; 204
2005; 174
2006; 79
2008; 18
1999; 49
2007; 100
2002; 13
1993; 85
2008; 9
2004; 5
2005; 65
2003; 278
2005; 66
2007; 16
2007; 178
2004; 58
2002; 168
2004; 172
2002; 21
1999; 37
2008; 27
1999; 59
2004; 171
2005; 73
2005; 97
2007; 7
2007; 60
2007; 44
2009; 1
2007; 67
2007; 46
2003; 21
e_1_2_1_41_2
e_1_2_1_40_2
e_1_2_1_22_2
e_1_2_1_23_2
e_1_2_1_20_2
e_1_2_1_21_2
e_1_2_1_26_2
e_1_2_1_27_2
e_1_2_1_24_2
e_1_2_1_25_2
e_1_2_1_28_2
e_1_2_1_29_2
Olumi AF (e_1_2_1_38_2) 1999; 59
e_1_2_1_6_2
e_1_2_1_30_2
e_1_2_1_7_2
e_1_2_1_4_2
e_1_2_1_5_2
e_1_2_1_2_2
e_1_2_1_11_2
e_1_2_1_34_2
e_1_2_1_3_2
e_1_2_1_12_2
e_1_2_1_33_2
e_1_2_1_32_2
e_1_2_1_10_2
e_1_2_1_31_2
e_1_2_1_15_2
e_1_2_1_16_2
e_1_2_1_37_2
e_1_2_1_13_2
e_1_2_1_36_2
e_1_2_1_14_2
e_1_2_1_35_2
e_1_2_1_19_2
e_1_2_1_8_2
e_1_2_1_17_2
e_1_2_1_9_2
e_1_2_1_18_2
e_1_2_1_39_2
References_xml – volume: 16
  start-page: 352
  year: 2007
  end-page: 355
  article-title: Toll‐like receptor 4 genetic variation and advanced prostate cancer risk
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 85
  start-page: 200
  year: 1993
  end-page: 206
  article-title: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer
  publication-title: J Natl Cancer Inst
– volume: 67
  start-page: 10519
  year: 2007
  end-page: 10527
  article-title: Activation of Toll‐like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo
  publication-title: Cancer Res
– volume: 18
  start-page: 315
  year: 2008
  end-page: 319
  article-title: Inflammation, infection, and prostate cancer
  publication-title: Curr Opin Urol
– volume: 58
  start-page: 121
  year: 2004
  end-page: 129
  article-title: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer
  publication-title: Prostate
– volume: 59
  start-page: 5002
  year: 1999
  end-page: 5011
  article-title: Carcinoma‐associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate
  publication-title: Cancer Res
– volume: 74
  start-page: 6973
  year: 2006
  end-page: 6981
  article-title: Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll‐like receptors 4 and 2 and MyD88 to the inclusion
  publication-title: Infect Immun
– volume: 7
  start-page: 256
  year: 2007
  end-page: 269
  article-title: Inflammation in prostate carcinogenesis
  publication-title: Nat Rev Cancer
– volume: 60
  start-page: 372
  year: 2007
  end-page: 380
  article-title: The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll‐like receptor 4
  publication-title: Neurosurgery
– volume: 9
  start-page: 361
  year: 2008
  end-page: 368
  article-title: TRAM couples endocytosis of Toll‐like receptor 4 to the induction of interferon‐beta
  publication-title: Nat Immunol
– volume: 204
  start-page: 1487
  year: 2007
  end-page: 1495
  article-title: Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo
  publication-title: J Exp Med
– volume: 100
  start-page: 733
  year: 2007
  end-page: 737
  article-title: The role of inflammation and infection in the pathogenesis of prostate carcinoma
  publication-title: BJU Int
– volume: 79
  start-page: 989
  year: 2006
  end-page: 998
  article-title: Prostate epithelial cells can act as early sensors of infection by up‐regulating TLR4 expression and pro‐inflammatory mediators upon LPS stimulation
  publication-title: J Leukoc Biol
– volume: 13
  start-page: 72
  year: 2002
  end-page: 79
  article-title: Meta‐analysis of measures of sexual activity and prostate cancer
  publication-title: Epidemiology
– volume: 178
  start-page: 3186
  year: 2007
  end-page: 3197
  article-title: TLR9 expression and function is abolished by the cervical cancer‐associated human papillomavirus type 16
  publication-title: J Immunol
– volume: 64
  start-page: 2918
  year: 2004
  end-page: 2922
  article-title: Sequence variants of toll‐like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study
  publication-title: Cancer Res
– volume: 172
  start-page: 1256
  year: 2004
  end-page: 1265
  article-title: Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll‐like receptor 2 ligands
  publication-title: J Immunol
– volume: 21
  start-page: 3
  year: 2002
  end-page: 16
  article-title: The diet, prostate inflammation, and the development of prostate cancer
  publication-title: Cancer Metastasis Rev
– volume: 278
  start-page: 32552
  year: 2003
  end-page: 32560
  article-title: Toll‐like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori‐induced NF‐kappa B activation and chemokine expression by epithelial cells
  publication-title: J Biol Chem
– volume: 174
  start-page: 5781
  year: 2005
  end-page: 5788
  article-title: NF‐kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments
  publication-title: J Immunol
– volume: 1
  start-page: 59
  year: 2009
  end-page: 68
  article-title: Toll‐like receptor‐9 expression is inversely correlated with estrogen receptor status in breast cancer
  publication-title: J Innate Immun
– volume: 65
  start-page: 11771
  year: 2005
  end-page: 11778
  article-title: Sequence variants of Toll‐like receptor 4 and susceptibility to prostate cancer
  publication-title: Cancer Res
– volume: 97
  start-page: 525
  year: 2005
  end-page: 532
  article-title: Sequence variants in Toll‐like receptor gene cluster (TLR6‐TLR1‐TLR10) and prostate cancer risk
  publication-title: J Natl Cancer Inst
– volume: 168
  start-page: 1435
  year: 2002
  end-page: 1440
  article-title: Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll‐like receptor 4 and MD2 in a MyD88‐dependent pathway
  publication-title: J Immunol
– volume: 7
  start-page: 353
  year: 2007
  end-page: 364
  article-title: The family of five: TIR‐domain‐containing adaptors in Toll‐like receptor signalling
  publication-title: Nat Rev Immunol
– volume: 92
  start-page: 4337
  year: 1995
  end-page: 4341
  article-title: Oxidative DNA damage and senescence of human diploid fibroblast cells
  publication-title: Proc Natl Acad Sci
– volume: 49
  start-page: 8
  year: 1999
  end-page: 31
  article-title: Cancer statistics, 1999
  publication-title: CA Cancer J Clin
– volume: 66
  start-page: 2
  year: 2005
  end-page: 8
  article-title: Chronic bacterial prostatitis: An evolving clinical enigma
  publication-title: Urology
– volume: 44
  start-page: 2850
  year: 2007
  end-page: 2859
  article-title: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance
  publication-title: Mol Immunol
– volume: 46
  start-page: 941
  year: 2007
  end-page: 947
  article-title: Increased toll‐like receptor 9 expression in cervical neoplasia
  publication-title: Mol Carcinog
– volume: 171
  start-page: S36
  year: 2004
  end-page: S40
  article-title: Epidemiology of inflammation and prostate cancer
  publication-title: J Urol
– volume: 27
  start-page: 218
  year: 2008
  end-page: 224
  article-title: TLR signaling by tumor and immune cells: A double‐edged sword
  publication-title: Oncogene
– volume: 37
  start-page: 1863
  year: 1999
  end-page: 1870
  article-title: Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and “nonbacterial” prostatitis
  publication-title: J Clin Microbiol
– volume: 18
  start-page: 300
  year: 2008
  end-page: 305
  article-title: Increased expression of Toll‐like receptor 5 during progression of cervical neoplasia
  publication-title: Int J Gynecol Cancer
– volume: 27
  start-page: 161
  year: 2008
  end-page: 167
  article-title: Toll‐like receptor 9 (TLR9) agonists in the treatment of cancer
  publication-title: Oncogene
– volume: 67
  start-page: 774
  year: 2007
  end-page: 781
  article-title: Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro
  publication-title: Prostate
– volume: 75
  start-page: 664
  year: 2006
  end-page: 672
  article-title: Toll‐like receptor 4 in rat prostate: Modulation by testosterone and acute bacterial infection in epithelial and stromal cells
  publication-title: Biol Reprod
– volume: 21
  start-page: 335
  year: 2003
  end-page: 346
  article-title: Toll‐like receptors
  publication-title: Annu Rev Immunol
– volume: 73
  start-page: 687
  year: 2005
  end-page: 694
  article-title: Oral mucosal endotoxin tolerance induction in chronic periodontitis
  publication-title: Infect Immun
– volume: 5
  start-page: 987
  year: 2004
  end-page: 995
  article-title: Toll‐like receptor control of the adaptive immune responses
  publication-title: Nat Immunol
– ident: e_1_2_1_5_2
  doi: 10.1097/01.ju.0000108131.43160.77
– ident: e_1_2_1_19_2
  doi: 10.4049/jimmunol.172.2.1256
– ident: e_1_2_1_36_2
  doi: 10.4049/jimmunol.178.5.3186
– ident: e_1_2_1_40_2
  doi: 10.1128/IAI.00593-06
– ident: e_1_2_1_20_2
  doi: 10.1093/jnci/85.3.200
– ident: e_1_2_1_34_2
  doi: 10.1111/j.1525-1438.2007.01008.x
– ident: e_1_2_1_15_2
  doi: 10.1189/jlb.1005597
– ident: e_1_2_1_3_2
  doi: 10.1097/MOU.0b013e3282f9b3b7
– ident: e_1_2_1_9_2
  doi: 10.1038/ni1112
– ident: e_1_2_1_28_2
  doi: 10.1038/sj.onc.1210911
– volume: 59
  start-page: 5002
  year: 1999
  ident: e_1_2_1_38_2
  article-title: Carcinoma‐associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate
  publication-title: Cancer Res
  contributor:
    fullname: Olumi AF
– ident: e_1_2_1_25_2
  doi: 10.1073/pnas.92.10.4337
– ident: e_1_2_1_2_2
  doi: 10.3322/canjclin.49.1.8
– ident: e_1_2_1_22_2
  doi: 10.1074/jbc.M305536200
– ident: e_1_2_1_6_2
  doi: 10.1111/j.1464-410X.2007.07091.x
– ident: e_1_2_1_12_2
  doi: 10.1158/0008-5472.CAN-05-2078
– ident: e_1_2_1_14_2
  doi: 10.1093/jnci/dji070
– ident: e_1_2_1_32_2
  doi: 10.1227/01.NEU.0000249280.61761.2E
– ident: e_1_2_1_39_2
  doi: 10.1095/biolreprod.106.053967
– ident: e_1_2_1_24_2
  doi: 10.1023/A:1020110718701
– ident: e_1_2_1_37_2
  doi: 10.1159/000151602
– ident: e_1_2_1_35_2
  doi: 10.1002/mc.20325
– ident: e_1_2_1_10_2
  doi: 10.1084/jem.20070325
– ident: e_1_2_1_7_2
  doi: 10.1146/annurev.immunol.21.120601.141126
– ident: e_1_2_1_16_2
  doi: 10.1002/pros.10317
– ident: e_1_2_1_18_2
  doi: 10.4049/jimmunol.174.9.5781
– ident: e_1_2_1_29_2
  doi: 10.1038/sj.onc.1210904
– ident: e_1_2_1_23_2
  doi: 10.1097/00001648-200201000-00012
– ident: e_1_2_1_26_2
  doi: 10.1016/j.urology.2004.12.028
– ident: e_1_2_1_21_2
  doi: 10.4049/jimmunol.168.3.1435
– ident: e_1_2_1_27_2
  doi: 10.1128/JCM.37.6.1863-1870.1999
– ident: e_1_2_1_17_2
  doi: 10.1128/IAI.73.2.687-694.2005
– ident: e_1_2_1_8_2
  doi: 10.1038/nri2079
– ident: e_1_2_1_30_2
  doi: 10.1016/j.molimm.2007.01.022
– ident: e_1_2_1_11_2
  doi: 10.1158/0008-5472.CAN-03-3280
– ident: e_1_2_1_13_2
  doi: 10.1158/1055-9965.EPI-06-0429
– ident: e_1_2_1_33_2
  doi: 10.1158/0008-5472.CAN-07-0079
– ident: e_1_2_1_4_2
  doi: 10.1038/nrc2090
– ident: e_1_2_1_31_2
  doi: 10.1002/pros.20562
– ident: e_1_2_1_41_2
  doi: 10.1038/ni1569
SSID ssj0010002
Score 2.2275393
Snippet BACKGROUND Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of...
Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll-like receptors (TLRs) compose a family of receptors...
SourceID crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 1387
SubjectTerms Adenocarcinoma - immunology
Adenocarcinoma - pathology
Adenocarcinoma - physiopathology
Biological and medical sciences
Cell Line, Tumor
Chemokines - genetics
Cytokines - genetics
Gene Expression Regulation, Neoplastic
Gleason grade
Gynecology. Andrology. Obstetrics
Humans
inflammation
Male
Male genital diseases
Medical sciences
Nephrology. Urinary tract diseases
Prostate - pathology
Prostate - physiology
prostate cancer
Prostatic Neoplasms - immunology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - physiopathology
Prostatitis - immunology
Prostatitis - pathology
Prostatitis - physiopathology
Severity of Illness Index
Signal Transduction - immunology
Toll-like receptor 4
Toll-Like Receptor 4 - genetics
Toll-Like Receptor 4 - metabolism
tumor immunology
Tumors
Tumors of the urinary system
Up-Regulation - immunology
Urinary tract. Prostate gland
Title Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer
URI https://api.istex.fr/ark:/67375/WNG-SMLD1RJV-H/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpros.20984
https://www.ncbi.nlm.nih.gov/pubmed/19496069
Volume 69
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB5aF0IvbR5tqqYxCyk9FERsaaXVQi-hcWJC4pjYbXoTq32ASVCCZYOP_Qn9jf0lmVk5cnIJhBwEOuxKy87rm318A_C1Y7jqSI32rRMecoPpjtIqQl3G4CVc6rgnq-6PxOBPdtgjmpwf93dhan6IZsGNLMP7azJwVVT7K9JQdDBEty0zIgPFNMHf34iHzRYC2bpfYBGdED21aLhJo_1V10fR6A1N7IJOR6oKJ8jVlS0ehKaH8NXHn6P3Lxv5Orxb4k52UCvKBryy5SasnS131reg6i2WR2JLduPYGNXj_99_15Mry9An2ltMzRlnk5IhYGT0aQKpzBcAYfRMZhVTK1EzWt_1bTHyWiqQR19t-mnStekH-HXUG__sh8uCDKGOJYrSpDaSSulMmW5hYiGdszw2Visj0Jil0t1CoCe3TqfSOi6yxBjNY0RJhTOZjj9Cq7wp7SdgiCTjlEvt6DZ-YnQW6azjjMycS4UoogD27gWT39a8G3nNsBzlNNjcz18A37zMmiZqekUn1USSXw6O89HZ6WH34uR33g-g_UioTQdCiMRIFMB2LeXV3ySn7E4G8N0L84lh5MOL85F_-_ycxjvwtt6bkmE3-QKt2XRud-F1ZeZtr8p3Nrj46g
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxEB7xkEovQFvaLuVhiaqHSiuSXe96fegBQSCUJEUkLb1Zjh9SRLWgBCSO_Qn9jfwSZrxhA5dKiMNKe7B3Lc_r89j-BuBzw3LdkAbt22Q85haXO9roBHUZg5fwueeBrLrdF73fxUGLaHK-PdyFqfgh6oQbWUbw12TglJDenbGGoochvm1Z8HlY5DlqIt3gSE_rTQSy9pBiEY0YfbWo2UmT3VnfJ_Fokab2ls5H6glOka9qWzwKTo8BbIhAhysvHPsqLE-hJ9urdOUNzLnyLbzqTjfX38GkdTs9FVuyS88GqCF3f__9GV04hm7RXeHqnHE2KhliRkafJpzKQg0QRs_oesL0TNqMUryhLQZfRzXy6Kt1P0PqNl6Dn4etwX47ntZkiE0qUZo2d4nU2hTaNoc2FdJ7x1PrjLYC7Vlq0xwKdObOm1w6z0WRWWt4ikBp6G1h0vewUF6W7iMwBJNpzqXxdCE_s6ZITNHwVhbe50IMkwh2HiSjrirqDVWRLCeKBqvC_EXwJQitbqLHF3RYTWTqvHek-t3OQfPs-y_VjmDriVTrDgQSiZQogg-VmGd_k5wWeDKCr0Ga_xmGOj370Q9v689pvA1L7UG3ozrHvZNP8LraqpJxM9uAhevxjduE-Ym92Qp6fQ_dFf0S
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JTxsxFH4qIKFeWLoOWy2Beqg0IpnxjMcSF0SSBgppRGjLzXK8SBFoiBKQOPIT-hv7S3jPEyZwqVT1MJIPtsfy2z5v3wPYa1iuG9KgfZuMx9zickcbnaAuY_ASPvc8kFV3B6J3WbTaRJNz8PQWpuKHqDfcyDKCvyYDH1u_PycNRQdDdNuy4AuwxBGHE3N-mvbrMwQy9rDDIhoxumpRk5Mm-_O2L8LREs3sPV2P1FOcIV-ltngWm57j1xCAOqv_N_Q1WJkBT3ZYaco6vHLlG1g-mx2tv4Vp-352J7ZkN55doH78efh9PbpyDJ2iG-PanHE2KhkiRkZdE0plIQMIo290O2V6LmtGG7yhLoZeRxnyqNe6nSFlm7yDH532xVE3nmVkiE0qUZY2d4nU2hTaNoc2FdJ7x1PrjLYCrVlq0xwKdOXOm1w6z0WRWWt4ijBp6G1h0vewWN6U7iMwhJJpzqXx9Bw_s6ZITNHwVhbe50IMkwh2nwSjxhXxhqoolhNFg1Vh_iL4HGRWV9GTK7qqJjL1q_dVDc5OW83zk5-qG8HOC6HWDQgiEiVRBB8qKc__Jjkt72QEX4Iw_zIM1T__PgiljX-p_AmW-62OOj3ufduE19U5lYyb2RYs3k7u3DYsTO3dTtDqR9l_-7g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+Toll%E2%80%90like+receptor+4+in+the+prostate+gland+and+its+association+with+the+severity+of+prostate+cancer&rft.jtitle=The+Prostate&rft.au=Gatti%2C+Gerardo&rft.au=Quintar%2C+Amado+A.&rft.au=Andreani%2C+Virginia&rft.au=Nicola%2C+Juan+P.&rft.date=2009-09-15&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0270-4137&rft.eissn=1097-0045&rft.volume=69&rft.issue=13&rft.spage=1387&rft.epage=1397&rft_id=info:doi/10.1002%2Fpros.20984&rft.externalDBID=10.1002%252Fpros.20984&rft.externalDocID=PROS20984
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-4137&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-4137&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-4137&client=summon